Outlook Therapeutics shares are trading higher after the company announced it received FDA agreement under a SPA for the NORSE EIGHT clinical trial. Also, the company announced a private placement of up to $172 million to advance ONS-5010.
Benzinga Newsdesk - Jan 23, 2024, 12:09PM